Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/06/008786
CTRI/2017/06/008786
Completed
Phase 2

An Open Label, Prospective, Multi Center, Clinical study to evaluate efficacy and safety of Arthrohills Capsules in subjects suffering from Osteoarthritis of Knee(s) - NI

Herbal Hills Ltd0 sites33 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: M179- Osteoarthritis of knee, unspecified

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: M179- Osteoarthritis of knee, unspecified
Sponsor
Herbal Hills Ltd
Enrollment
33
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 7, 2017
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Herbal Hills Ltd

Eligibility Criteria

Inclusion Criteria

  • •1\. Symptoms of osteoarthritis in one or both knee joints for a minimum of six months and maximum for five years
  • •2\. History of knee pain due to osteoarthritis requiring the use of NSAIDs, Acetaminophen, or another analgesic agent on a regular basis i.e. greater than or equal to three days per week for at least six months before the screening visit
  • •3\. OA confirmed by radiographs and diagnosed according to ACR diagnostic Criteria
  • •4\. Subjects with pain VAS greater than or equal to 40 mm on weight bearing activities

Exclusion Criteria

  • •1\. Rheumatoid arthritis, gout, pseudo gout, inflammatory arthritis, Pagets disease of bone, chronic pain syndrome, fibromyalgia, or another major joint disease
  • •2\. History of surgery, including arthroscopy, or major trauma to the study joint in the previous six months before the screening visit
  • •3\. Subjects requiring knee arthroplasty within 6 months of screening or anticipating any need for a surgical procedure on the index joint during the study
  • •4\. Use of systemic corticosteroids within 2 months of screening, or intra\-articular visco supplementation within the past 3 months
  • •5\. Subjects having diabetes mellitus, tuberculosis, HIV, Ischemic Heart Disease
  • •6\. Known other major medical or surgical disease
  • •7\. Pregnancy and Lactation.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Clinical study on AYUARTIS Capsules in OsteoarthritisHealth Condition 1: M179- Osteoarthritis of knee, unspecified
CTRI/2017/06/008790Welex Laboratories Pvt Ltd31
Completed
Phase 2
Clinical trial to study the Suitability for Consumption of Chyawanprakash in Controlled Type II Diabetic Patients.Health Condition 1: null- Type 2 Diabetes mellitus
CTRI/2013/04/003553Dabur Research Development Centre DRDC120
Completed
Phase 3
Herbal Steaminhaler clinical trial on COVID patients
CTRI/2020/06/026181HAOMA WELLNESS CENTER40
Completed
Phase 2
Clinical study on Ayuvita Forte Capsule in irregular periods with cysts in ovary.
CTRI/2019/11/022183Welex Laboratories Pvt Ltd25
Recruiting
Phase 1
A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment)Hepatocellular CarcinomaMedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
CTIS2023-508945-41-00Biocompatibles UK Limited107